BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

NEW YORK (TheStreet) -- Shares of BioLineRx  (BLRX)  were surging 26.73% to $1.28 on heavy trading volume late afternoon Friday as the Israeli drug developer signed a liver treatment licensing agreement with BGN Technologies and Hadasit

BGN Technologies is the technology transfer and commercialization company of Ben-Gurion University, a public research university in Israel, the company said in a statement. 

Hadasit is the technology transfer company of the Hadassah Medical Organization, a hospital in Israel. 

The license allows for the development of a novel treatment, called BL-1220, for various liver failure conditions including end-stage liver disease and non-alcoholic steatohepatitis (NASH). 

The agreement was signed as part of BioLineRx's strategic partnership with Swiss pharmaceutical company Novartis (NVS). 

More than 7.95 million of the company's shares have changed hands so far today vs. its average volume of 323,826 shares per day.

BLRX Chart BLRX data by YCharts

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices